懂色一区二区三区久久久,成人高清无码视频,中文字幕只是让你摩擦一下,国产精品人人爽人人做Av片

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73198KIF5B（E15）-RET（E12） V804L/BaF3

KIF5B（E15）-RET（E12） V804L/BaF3
名稱 KIF5B（E15）-RET（E12） V804L/BaF3
型號 CBP73198
報價
特點 KIF5B（E15）-RET（E12） [V804L]/BaF3,母細胞：BaF3，凍存條件：90% FBS+10% DMSO
  • 詳細內(nèi)容
CBP73198
I. Introduction

Cell Line Name：

KIF5B(E15)-RET(E12) [V804L]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET [V804L]/BaF3

CBP73198 WB.png


2. Sanger of KIF5B-RET [V804L]/BaF3

CBP73198 sanger1.png


CBP73198 sanger2.png


3. Anti-proliferation assay

CBP73198 fig.jpg

Figure 4.CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804L Cells (C1).




如果你對CBP73198KIF5B（E15）-RET（E12） V804L/BaF3感興趣，想了解更詳細的產(chǎn)品信息，填寫下表直接與廠家聯(lián)系：


留言框

  • 產(chǎn)品：

  • 您的單位：

  • 您的姓名：

  • 聯(lián)系電話：

  • 常用郵箱：

  • 省份：

  • 詳細地址：

  • 補充說明：

  • 驗證碼：

    請輸入計算結(jié)果（填寫阿拉伯數(shù)字），如：三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
在线免费av电影| 男女Xx00| 98av| 国产精品久久久久久久久费观看| A V色| 久久 免费不卡| 国产乱国产乱| 亚洲色婷婷一区二区三区| 亚洲国产av一区二区| 欧美高清videos高潮hd| 久久久久国产精品一区二区| 琪琪色av| 在线91av| 亚洲区无码99Pro| 每日一个精品人妻m88| 黄瓜成人精品日韩在线观看| 亚洲Av之男人的天堂| 呦女| 欧美精品一区二区三千区| 99久一区| 久青青在线观看视频国产| 亚洲AV无码国产精品麻豆天美| 高要市| 人妻中文激情| 久久香蕉国产线看观看av| 99精品免费久久久久久久| av天天看| 亚洲草原天堂视频| 久久.com| 在线观看欧美性爱中文字幕| 国产亚洲av无码专区a∨麻豆| 国产在线播放| 亚洲午夜久久久| 亚洲色图 欧美色图久久| 国产午夜AV| 69久久| 国产色老精品| 黑人巨大精品欧美一区| 久久99精品国产自在现线| www.成人基地| 欧日一级黄色片|